56 related articles for article (PubMed ID: 18348656)
1. Transforming growth factor β-1 (TGF-β1) is a serum biomarker of radiation induced fibrosis in patients treated with intracavitary accelerated partial breast irradiation: preliminary results of a prospective study.
Boothe DL; Coplowitz S; Greenwood E; Barney CL; Christos PJ; Parashar B; Nori D; Chao KS; Wernicke AG
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1030-6. PubMed ID: 24139518
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of phosphorylated HER-2 in HER-2+ primary breast cancer.
Hayashi N; Iwamoto T; Gonzalez-Angulo AM; Ferrer-Lozano J; Lluch A; Niikura N; Bartholomeusz C; Nakamura S; Hortobagyi GN; Ueno NT
Oncologist; 2011; 16(7):956-65. PubMed ID: 21712485
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of apolipoprotein E correlates with disease progression and poor prognosis in breast cancer.
Xu X; Wan J; Yuan L; Ba J; Feng P; Long W; Huang H; Liu P; Cai Y; Liu M; Luo J; Li L
Tumour Biol; 2016 Oct; ():. PubMed ID: 27709551
[TBL] [Abstract][Full Text] [Related]
4. Relationship between serum TGF- β 1, MMP-9 and IL-1β and pathological features and prognosis in breast cancer.
Cai S; Zheng J; Song H; Wu H; Cai W
Front Genet; 2022; 13():1095338. PubMed ID: 36712861
[TBL] [Abstract][Full Text] [Related]
5. The expression and prognostic significance of Topo-II and c-erbB-2 in breast cancer.
Hua S; Chuanbo F; Zhonglin W; Shuangjiu Z; Xinwen Z
Minerva Med; 2020 Jul; ():. PubMed ID: 32683851
[TBL] [Abstract][Full Text] [Related]
6. Long Non-coding RNA N1LR Protects Against Myocardial Ischemic/Reperfusion Injury Through Regulating the TGF-β Signaling Pathway.
Du L; Chen J; Wu Y; Xia G; Chen M; Zhao P; Wang Y; Yao D; Liu F; Zhang L; Wang X; Yang Y; Wang L
Front Cardiovasc Med; 2021; 8():654969. PubMed ID: 34485393
[TBL] [Abstract][Full Text] [Related]
7. Chemoradiation induces epithelial-to-mesenchymal transition in esophageal adenocarcinoma.
Steins A; Ebbing EA; Creemers A; van der Zalm AP; Jibodh RA; Waasdorp C; Meijer SL; van Delden OM; Krishnadath KK; Hulshof MCCM; Bennink RJ; Punt CJA; Medema JP; Bijlsma MF; van Laarhoven HWM
Int J Cancer; 2019 Nov; 145(10):2792-2803. PubMed ID: 31018252
[TBL] [Abstract][Full Text] [Related]
8. A targeted transforming growth factor-beta (TGF-β) blocker, TTB, inhibits tumor growth and metastasis.
Zhou C; Li J; Lin L; Shu R; Dong B; Cao D; Li Q; Wang Z
Oncotarget; 2018 May; 9(33):23102-23113. PubMed ID: 29796175
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer survival among young women: a review of the role of modifiable lifestyle factors.
Brenner DR; Brockton NT; Kotsopoulos J; Cotterchio M; Boucher BA; Courneya KS; Knight JA; Olivotto IA; Quan ML; Friedenreich CM
Cancer Causes Control; 2016 Apr; 27(4):459-72. PubMed ID: 26970739
[TBL] [Abstract][Full Text] [Related]
10. High serum transforming growth factor beta 1 (TGFB1) level predicts better survival in breast cancer.
Ciftci R; Tas F; Yasasever CT; Aksit E; Karabulut S; Sen F; Keskin S; Kilic L; Yildiz I; Bozbey HU; Duranyildiz D; Vatansever S
Tumour Biol; 2014 Jul; 35(7):6941-8. PubMed ID: 24740564
[TBL] [Abstract][Full Text] [Related]
11. Serum concentrations of transforming growth factor-Beta 1 in predicting the occurrence of diabetic retinopathy in juvenile patients with type 1 diabetes mellitus.
Zorena K; Malinowska E; Raczyńska D; Myśliwiec M; Raczyńska K
J Diabetes Res; 2013; 2013():614908. PubMed ID: 23671881
[TBL] [Abstract][Full Text] [Related]
12. Targeting TGF-β signaling in cancer.
Katz LH; Li Y; Chen JS; Muñoz NM; Majumdar A; Chen J; Mishra L
Expert Opin Ther Targets; 2013 Jul; 17(7):743-60. PubMed ID: 23651053
[TBL] [Abstract][Full Text] [Related]
13. Transforming growth factor β signaling pathway associated gene polymorphisms may explain lower breast cancer risk in western Indian women.
Joshi NN; Kale MD; Hake SS; Kannan S
PLoS One; 2011; 6(8):e21866. PubMed ID: 21829601
[TBL] [Abstract][Full Text] [Related]
14. Alterations of ER, PR, HER-2/neu, and P53 protein expression in ductal breast carcinomas and clinical implications.
Liu C; Zhang H; Shuang C; Lu Y; Jin F; Xu H; Lu P
Med Oncol; 2010 Sep; 27(3):747-52. PubMed ID: 19657752
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism.
Papadopoulou E; Anagnostopoulos K; Tripsianis G; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
Neoplasma; 2008; 55(3):229-38. PubMed ID: 18348656
[TBL] [Abstract][Full Text] [Related]
16. The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome.
Papadopoulou E; Tripsianis G; Anagnostopoulos K; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
Neoplasma; 2008; 55(2):113-21. PubMed ID: 18237248
[TBL] [Abstract][Full Text] [Related]
17. Allelic imbalance of HER-2 codon 655 polymorphism among different religious/ethnic populations of northern Greece and its association with the development and the malignant phenotype of breast cancer.
Papadopoulou E; Simopoulos K; Tripsianis G; Tentes I; Anagnostopoulos K; Sivridis E; Galazios G; Kortsaris A
Neoplasma; 2007; 54(5):365-73. PubMed ID: 17918664
[TBL] [Abstract][Full Text] [Related]
18. Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer.
Souder C; Leitzel K; Ali SM; Demers L; Evans DB; Chaudri-Ross HA; Hackl W; Hamer P; Carney W; Lipton A
Cancer; 2006 Nov; 107(10):2337-45. PubMed ID: 17048231
[TBL] [Abstract][Full Text] [Related]
19. Tumor markers in breast cancer--evaluation of their clinical usefulness.
Marić P; Ozretić P; Levanat S; Oresković S; Antunac K; Beketić-Oresković L
Coll Antropol; 2011 Mar; 35(1):241-7. PubMed ID: 21661378
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
